Viking Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Viking Therapeutics has a total shareholder equity of $933.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $967.5M and $33.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$962.98m |
Equity | US$933.89m |
Total liabilities | US$33.63m |
Total assets | US$967.52m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0VQA's short term assets ($966.3M) exceed its short term liabilities ($32.8M).
Long Term Liabilities: 0VQA's short term assets ($966.3M) exceed its long term liabilities ($852.0K).
Debt to Equity History and Analysis
Debt Level: 0VQA is debt free.
Reducing Debt: 0VQA had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0VQA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 0VQA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25.3% each year